WO2021154966A1 - Compounds and compositions for use in treating skin disorders - Google Patents

Compounds and compositions for use in treating skin disorders Download PDF

Info

Publication number
WO2021154966A1
WO2021154966A1 PCT/US2021/015449 US2021015449W WO2021154966A1 WO 2021154966 A1 WO2021154966 A1 WO 2021154966A1 US 2021015449 W US2021015449 W US 2021015449W WO 2021154966 A1 WO2021154966 A1 WO 2021154966A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
halo
pyrrolidin
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/015449
Other languages
English (en)
French (fr)
Inventor
Xinyuan Wu
Bertrand L. Chenard
Nili Claudia SCHUTZ
Dov Terkieltaub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kamari Pharma Ltd
Original Assignee
Kamari Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2021212754A priority Critical patent/AU2021212754A1/en
Priority to BR112022014933-6A priority patent/BR112022014933B1/pt
Priority to EP21748179.5A priority patent/EP4096661B1/en
Priority to IL295088A priority patent/IL295088B2/en
Priority to CA3168103A priority patent/CA3168103A1/en
Priority to EP25165470.3A priority patent/EP4574822A3/en
Priority to JP2022545405A priority patent/JP7785004B2/ja
Priority to ES21748179T priority patent/ES3032872T3/es
Priority to NZ790364A priority patent/NZ790364A/en
Application filed by Kamari Pharma Ltd filed Critical Kamari Pharma Ltd
Priority to CN202180024047.XA priority patent/CN115335050B/zh
Priority to KR1020227025104A priority patent/KR102735703B1/ko
Priority to CN202410539437.6A priority patent/CN118702672A/zh
Priority to PL21748179.5T priority patent/PL4096661T3/pl
Publication of WO2021154966A1 publication Critical patent/WO2021154966A1/en
Anticipated expiration legal-status Critical
Priority to JP2025146979A priority patent/JP2025175030A/ja
Priority to IL324069A priority patent/IL324069A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present disclosure provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein:
  • A is bond, aryl, or heteroaryl
  • X 1 and X 2 together are oxo, or each of X 1 and X 2 is H;
  • R1 is C1-C3 haloalkyl and n is 1.
  • W is is -C(O)-.
  • the compound of Formula (E) is
  • q is 1 or 2
  • R 3 is C1-C6 alkyl or C3-C8 cycloalkyl.
  • one of X, Y, and Z is absent.
  • Y and Z are absent.
  • X, Y, and Z are absent.
  • a and E are phenyl.
  • the present disclosure provides a compound of Formula (XVII): or a pharmaceutically acceptable salt thereof, wherein:
  • A is bond, aryl, or heteroaryl
  • E is aryl, heteroaryl, C3-C8 cycloalkyl, or C3-C8 cycloalkenyl
  • the present disclosure provides a compound of Formula (XXI) or a pharmaceutically acceptable salt thereof, wherein:
  • G is aryl, heteroaryl, C3-C8 cycloalkyl, or C3-C8 heterocycloalkyl; each R 1 is independently cyano, nitro, hydroxy, halo, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C6 alkyl, C1-C6 alkoxy, aryl, -N(R a )(R b ), -C(0)R c , -C0 2 R c , -C(0)N(R a )(R b ), -S0 2 N(R a )(R b ), or -SOR c , or two R 1 groups together form a ring system, e.g., each R 2 and R 3 is independently cyano, nitro, hydroxy, halo, C1-C3 haloalkyl, Ci- C3 haloalkoxy, C1-C6 alkyl (e.g
  • q is 1 or 2
  • R 3 is C1-C6 alkyl or C3-C8 cycloalkyl.
  • z is 1, and Y 1 and Y 2 together are oxo.
  • E is phenyl and L is bond or -0-.
  • X is -CH-
  • R 2 is -CH2OH
  • L is bond or -0-
  • q is
  • X is -N- or -CH-
  • L is bond, -(CR a R b ) m- , -0-, -C(O)-, -C(0)N(R a )-, or -CH(OR c )-; each R 2 and R 3 is independently cyano, nitro, hydroxy, halo, C1-C3 haloalkyl, Ci- C3 haloalkoxy, C1-C6 alkyl (e.g., -CH(0H)CH20H), C1-C6 alkoxy, C3-C8 cycloalkyl, aryl, -N(R a )(R b ), -C(0)R c , -C0 2 R c , -C(0)N(R a )(R b ), -S0 2 N(R a )(R b ), or -SOR c ; each R 4 , R 5 , and R 6 is independently cyano, C1-C6 al
  • R 5 is cyano, C1-C6 alkyl, C1-C6 alkoxyl, halo, C1-C3 haloalkyl, or -C(0)N(R a )(R b ); each R a and R b is independently H, hydroxyl, -OR c , -N(R C )(R C ), C1-C6 alkyl, -C(0)R c , or -C(0)0R c ; and
  • each of A, E and G is independently of the other is cycloalkenyl or heterocycloalkenyl.
  • each one of A, E and G in the compounds of the invention is independently of the other selected from an aryl comprising five atoms or a aryl comprising six atoms.
  • E is selected from phenyl, pyridine, pyrazine, pyrimidine, pyridazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine.
  • p is 1 or 2.
  • n is 2 and R 1 is at least one of methyl and hydroxy.
  • R 3 is cyclopropyl and fluorine.
  • q is 1 or 2 and R 3 is at least one of halo, C1-C6 alkyl,
  • q is 1
  • u is 1
  • R 3 is at least one of halo, C1-C6 alkyl, Ci- Ce alkoxy, or C3-C8 cycloalkyl and R 7 is halo.
  • R 3 is fluorine, cyclopropyl, methyl, ethyl or propyl.
  • racemic mixture also denoted as racemate as used denotes that for a chiral compound, there are equal amounts of left- and right-handed enantiomers.
  • the compound includes a mixture of 50% left-hand enantiomer and 50% right-hand enantiomer.
  • dialkylamino refers to a group of formula - N(alkyl) 2 , wherein the two alkyl groups each independently has, 1 to 6 carbons.
  • aryl refers to a polyunsaturated, aromatic, hydrocarbon moiety which can be a single ring or multiple rings (e.g., 1 to 2 rings) which are fused together or linked covalently, having from six to twelve carbon atoms (i.e. C6-C12 aryl).
  • Non-limiting examples of aryl groups include phenyl, 1 -naphthyl, 2-naphthyl, and 4- biphenyl.
  • urea refers to -NR a -C(0)-NR3 ⁇ 4 or -NR a -C(0)NR a -, wherein
  • TRPV3 is provided in accordance with some emnodimetns by a protein accession number Q8NET8.
  • the compounds of the invention may be administrated in combination with a second active agent.
  • TrpAl TRP channel with major role in itch transmission
  • TrpAl is increased in nerve fibers, keratinocytes and tryptase positive mast cells from lesional skin of atopic dermatitis patients.
  • dermal cells in healthy skin have minimal expression of TrpAl.
  • TrpV3 is also increased in atopic dermatitis lesional skin though its role in itch is not entirely clear.
  • Elevated TrpAl expression is also detected in postbum pruritus.
  • Levels of TrpAl and two other channels TrpV3 and TrpV4 are all higher in post-bum patients with pruritus comparing with post-bum patients without pmritus.
  • TrpV3 expression is mainly detected in keratinocytes.
  • Activation of TrpV3 can trigger release of multiple factors including PGE2, ATP, nitric oxide and NGF, contributing to the inflammation processes in dermatitis.
  • TrpV3 Gly573 mutations are detected in DS-Nh mice (Gly573Ser) and WBN/Kob-Ht rats (Gly573Cys), both spontaneous hairless mutant strains. These animals develop spontaneous dermatitis phenotypes including increased keratinocytes and pruritus.
  • the skin condition is pruritis.
  • the compound is administered enterally.
  • the compounds of the invention may be effectively dispersed or suspended or solubilized in a liquid medium to form a solution, a suspension or a dispersion that may be applied topically, sprayed onto the skin or delivered by contact via the use of a sponge, a plaster, a pad or any skin dressing.
  • controlled release of the compounds of such delivery systems may be essential.
  • the present disclosure provides a method for modulating the activity of a cation channel, for example a Ca +2 channel - e.g. TRPV3.
  • the methods of the invention comprise inhibiting the activity of a cation channel, for example a Ca +2 channel - e.g. TRPV3 activity in a cell.
  • the method comprising the step of contacting the cell with an effective amount of at least one compound having the general formula (I)-(XXXXIII) or a pharmaceutically acceptable salt or hydrate thereof including any stereoisomer thereof.
  • any assays performed to identify and/or characterize compounds that inhibit an activity of TRPV3 can be performed in a high-throughput fashion, or can be performed on a smaller scale examining individual compounds or small numbers of compounds. Additionally, any of these assays can be performed (i) as a primary assay to identify compounds that inhibit a function of TRPV3; (ii) as a secondary assay to assess the specificity of a compound with respect to its activity against other ion channels; (iii) as an assay used in a medicinal chemistry program to optimize subject compounds.
  • Step 7 4-(4-(2-isopropylphenoxy)-2-((tetrahydro-2H-pyran-2- yloxy)methyl)phenyl)pyrrolidin-2-one
  • the title compound was prepared following procedures described in Intermediate 5 step5 to give 4-(4-(2-isopropylphenoxy)-2-((tetrahydro-2H-pyran-2- yloxy)methyl)phenyl)pyrrolidin-2-one
  • Step 1 (R)-2-(3-hydroxypynOlidin-l-yl)benzonitrile
  • Step 1 (R)-5-fluoro-2-(3-(5-(trifluoromethyl)pyridin-2-yloxy)pyrrolidin-l- yl)benzonitrile
  • Example 45 (S)-N,N-dimethyl-l-(2-(3-(5-(trifluoromethyl)pyridin-2- yloxy)pyrrolidin-l-yl)phenyl) methanamine hydrochloride (Compound 1-61)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/US2021/015449 2020-01-29 2021-01-28 Compounds and compositions for use in treating skin disorders Ceased WO2021154966A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
NZ790364A NZ790364A (en) 2020-01-29 2021-01-28 Compounds and compositions for use in treating skin disorders
EP21748179.5A EP4096661B1 (en) 2020-01-29 2021-01-28 Compounds and compositions for use in treating skin disorders
CN202180024047.XA CN115335050B (zh) 2020-01-29 2021-01-28 用于治疗皮肤病症的化合物和组合物
CA3168103A CA3168103A1 (en) 2020-01-29 2021-01-28 Compounds and compositions for use in treating skin disorders
EP25165470.3A EP4574822A3 (en) 2020-01-29 2021-01-28 Compounds and compositions for use in treating skin disorders
JP2022545405A JP7785004B2 (ja) 2020-01-29 2021-01-28 皮膚障害の治療に使用するための化合物及び組成物
ES21748179T ES3032872T3 (en) 2020-01-29 2021-01-28 Compounds and compositions for use in treating skin disorders
AU2021212754A AU2021212754A1 (en) 2020-01-29 2021-01-28 Compounds and compositions for use in treating skin disorders
IL295088A IL295088B2 (en) 2020-01-29 2021-01-28 Compounds and preparations for use in the treatment of skin disorders
BR112022014933-6A BR112022014933B1 (pt) 2020-01-29 2021-01-28 Compostos ou sal farmaceuticamente aceitável dos mesmos e usos dos mesmos
KR1020227025104A KR102735703B1 (ko) 2020-01-29 2021-01-28 피부 장애 치료에서 사용을 위한 화합물 및 조성물
CN202410539437.6A CN118702672A (zh) 2020-01-29 2021-01-28 用于治疗皮肤病症的化合物和组合物
PL21748179.5T PL4096661T3 (pl) 2020-01-29 2021-01-28 Związki i kompozycje do zastosowania w leczeniu zaburzeń skóry
JP2025146979A JP2025175030A (ja) 2020-01-29 2025-09-04 皮膚障害の治療に使用するための化合物及び組成物
IL324069A IL324069A (en) 2020-01-29 2025-10-19 Compounds and compositions for use in treating skin disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062967500P 2020-01-29 2020-01-29
US62/967,500 2020-01-29

Publications (1)

Publication Number Publication Date
WO2021154966A1 true WO2021154966A1 (en) 2021-08-05

Family

ID=77079457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/015449 Ceased WO2021154966A1 (en) 2020-01-29 2021-01-28 Compounds and compositions for use in treating skin disorders

Country Status (13)

Country Link
US (2) US11807621B2 (https=)
EP (2) EP4096661B1 (https=)
JP (2) JP7785004B2 (https=)
KR (1) KR102735703B1 (https=)
CN (2) CN118702672A (https=)
AU (1) AU2021212754A1 (https=)
CA (1) CA3168103A1 (https=)
ES (1) ES3032872T3 (https=)
HU (1) HUE071972T2 (https=)
IL (2) IL295088B2 (https=)
NZ (1) NZ790364A (https=)
PL (1) PL4096661T3 (https=)
WO (1) WO2021154966A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214375A1 (en) * 2022-05-05 2023-11-09 Kamari Pharma Ltd. Methods of treating dermatological conditions and symptoms thereof
CN117164527A (zh) * 2022-05-25 2023-12-05 大连理工大学 一种钒催化杂环芳香腈水解制备杂环芳香酰胺的方法
WO2024099404A1 (zh) 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种含氮螺环类化合物、药物组合物以及其用途
EP4617267A4 (en) * 2022-11-10 2026-02-18 Prime Gene Therapeutics Co Ltd Thioether compound having mild medicinal properties and its use, pharmaceutical composition and associated uses

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021154966A1 (en) 2020-01-29 2021-08-05 Kamari Pharma Ltd. Compounds and compositions for use in treating skin disorders
CN117624036A (zh) * 2023-10-30 2024-03-01 爱斯特（成都）生物制药股份有限公司 一种制备6-溴-3-氟-2-吡啶甲醛的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7818805B2 (en) 2004-09-09 2010-10-19 Avaya Inc. Methods and systems for network traffic security
US9617214B2 (en) * 2013-11-08 2017-04-11 The Translational Genomics Research Institute Compounds for cognitive enhancement and methods of use thereof
US20180194768A1 (en) * 2015-04-24 2018-07-12 President And Fellows Of Harvard College Substrate selective inhibitors of insulin degrading enzyme (ide) and uses thereof
US11078188B2 (en) 2017-03-08 2021-08-03 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US4183931A (en) 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
EP0005501B1 (de) 1978-05-20 1981-11-25 Bayer Ag Heteroaryl-oxyessigsäureamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide
US4461896A (en) 1979-02-07 1984-07-24 Norwich Eaton Pharmaceuticals, Inc. 1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids
DE3018075A1 (de) 1980-05-10 1981-11-12 Bayer Ag, 5090 Leverkusen Mittel zur regulierung des pflanzenwachstums, deren herstellung und deren verwendung
JPS56158702A (en) 1980-05-12 1981-12-07 Nippon Tokushu Noyaku Seizo Kk Herbicide
US4273927A (en) 1980-08-14 1981-06-16 Morton-Norwich Products, Inc. Converting enzyme inhibitor
DE3038599A1 (de) 1980-10-13 1982-05-19 Bayer Ag, 5090 Leverkusen Substituierte benzazol-2-yl-oxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
DE3038652A1 (de) 1980-10-13 1982-05-19 Bayer Ag, 5090 Leverkusen 5-chlor-benzoxazol-2-yl-oxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US4509949A (en) 1983-06-13 1985-04-09 The B. F. Goodrich Company Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters
DE3418168A1 (de) 1984-05-16 1985-11-21 Bayer Ag, 5090 Leverkusen 6-chlorbenzazolyloxyacetamide
DE3422861A1 (de) 1984-06-20 1986-01-02 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von heteroaryloxyacetamiden
US5087445A (en) 1989-09-08 1992-02-11 Richardson-Vicks, Inc. Photoprotection compositions having reduced dermal irritation
US5075313A (en) 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
US5196427A (en) 1990-09-13 1993-03-23 Eli Lilly And Company 3-aryl-4(3H) quinazolinone CCK antagonists and pharmaceutical formulations thereof
DE4218433A1 (de) 1992-06-04 1993-12-09 Bayer Ag Fluorbenzoxazolyloxyacetamide
DE4219246A1 (de) 1992-06-12 1993-12-16 Bayer Ag Neue 2-(7-Chlor-2-benzoxazolyloxy)-acetamide
DE4230903A1 (de) 1992-09-16 1994-03-17 Bayer Ag Fluorbenzthiazolyloxyacetamide
FR2707639B1 (fr) 1993-06-30 1995-10-13 Pf Medicament Nouveaux composés indoliques dérivés d'arylamines comme ligands sélectifs des récepteurs 5HT1D et 5HT1B.
US5756502A (en) 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
CN1103772C (zh) 1996-05-15 2003-03-26 辉瑞大药厂 新的2,3－二取代－4(3h)－喹唑啉酮类化合物
EP0807633B1 (en) 1996-05-15 2002-11-06 Pfizer Inc. Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
TR199902094T2 (xx) 1997-02-28 1999-12-21 Prizer Products Inc. 3-Heteroareil-4(3H)-kinazolinonlar�n atropizomerleri.
SK113299A3 (en) 1997-02-28 2001-05-10 Pfizer Prod Inc Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
DE69809827D1 (de) 1997-03-31 2003-01-16 Korea Res Inst Chem Tech Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US6060479A (en) 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
JPH11279158A (ja) 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
JP4994552B2 (ja) 1999-09-16 2012-08-08 キュリス，インコーポレイテッド ヘッジホッグシグナル伝達経路のメディエーター、組成物及びそれらと関連する利用
US20030219806A1 (en) 2000-02-22 2003-11-27 Millennium Pharmaceuticals, Inc. Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
AU2001270240A1 (en) 2000-06-26 2002-01-08 Millennium Pharmaceuticals, Inc. Human calcium channels (48000; 52920) and uses thereof
GB2372993A (en) 2000-11-03 2002-09-11 Smithkline Beecham Plc Vanilloid Receptor 6
US20030027164A1 (en) 2000-12-01 2003-02-06 Gaughan Glen T. Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
EP1399558A2 (en) 2001-06-13 2004-03-24 Novartis AG Vanilloid receptor-related nucleic acids and polypeptides
US7053216B2 (en) 2001-11-19 2006-05-30 Iconix Pharmaceuticals, Inc. Modulators of Rho C activity
US20040110777A1 (en) 2001-12-03 2004-06-10 Annis Gary David Quinazolinones and pyridinylpyrimidinones for controlling invertebrate pests
US20040009537A1 (en) 2002-01-11 2004-01-15 Jack Roos Methods of modulating and of identifying agents that modulate intracellular calcium
TW200401770A (en) 2002-06-18 2004-02-01 Sankyo Co Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
MXPA05004328A (es) 2002-11-04 2005-08-02 Nps Pharma Inc Compuestos de quinazolinona como calciliticos.
DE10330157A1 (de) 2003-07-04 2005-02-03 Zf Friedrichshafen Ag Lastschaltgetriebe für Baumaschinen, insbesondere für Baggerlader und Telehandler
GB0317516D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
ATE532509T1 (de) 2003-09-11 2011-11-15 Tibotec Pharm Ltd Mittel zur hemmung des eintritts des hiv-virus
DE10351087A1 (de) 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
CA2545725A1 (en) 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
EA010132B1 (ru) * 2003-12-22 2008-06-30 Пфайзер Инк. Производные триазола в качестве антагонистов вазопрессина
EP1722783A4 (en) 2004-03-08 2009-08-12 Wyeth Corp MODULATORS OF THE ION CHANNEL FUNCTION
US20050202539A1 (en) 2004-03-11 2005-09-15 Hydra Biosciences System for screening eukaryotic membrane proteins
US20070265289A1 (en) * 2004-04-15 2007-11-15 Yoshinori Okamoto 2-Aminopyrimidine Derivative
EP1750715A1 (en) 2004-06-04 2007-02-14 Icos Corporation Methods for treating mast cell disorders
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
EP2392328A1 (en) 2005-05-09 2011-12-07 Hydra Biosciences, Inc. Compounds for modulating TRPV3 Function
US8916550B2 (en) 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
GB0509573D0 (en) 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
US20090298856A1 (en) 2005-05-11 2009-12-03 Rebecca Elizabeth Brown 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1)
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
JP5116687B2 (ja) * 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
US7893260B2 (en) 2005-11-04 2011-02-22 Hydra Biosciences, Inc. Substituted quinazolin-4-one compounds for antagonizing TRPV3 function
US7998980B2 (en) 2006-09-15 2011-08-16 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
US20090306163A1 (en) 2008-06-10 2009-12-10 Pamela Renee Lipkin Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling
KR101034300B1 (ko) 2008-12-02 2011-05-16 고려대학교 산학협력단 Ｔｒｐｖ３ 활성 억제 약물 및 이의 활용
US8318928B2 (en) * 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
US8318759B2 (en) * 2009-02-18 2012-11-27 Hoffmann-La Roche Inc. Pyrrolidine derivatives as NK3 receptor antagonists
US8614242B2 (en) * 2010-10-21 2013-12-24 Bayer Intellectual Property Gmbh 1-(heterocyclic carbonyl)-2-substituted pyrrolidines
EP2632551B1 (en) * 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
TW201336847A (zh) * 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
US20140018435A1 (en) 2012-06-06 2014-01-16 University Of Illinois Chicago Transdermal Delivery of Therapeutic Agents Using Poly (Amidoamine) Dendrimers
AR096151A1 (es) * 2013-05-01 2015-12-09 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
US9562035B2 (en) * 2013-12-03 2017-02-07 Janssen Pharmaceutica Nv Benzamide derivative useful as FASN inhibitors for the treatment of cancer
JP2017100948A (ja) * 2014-04-01 2017-06-08 大日本住友製薬株式会社 ４−アリールイミダゾール誘導体
CN107912040B (zh) * 2014-10-10 2021-04-06 基因泰克公司 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
CN107417687A (zh) * 2016-05-24 2017-12-01 中国科学院上海药物研究所 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
WO2021154966A1 (en) 2020-01-29 2021-08-05 Kamari Pharma Ltd. Compounds and compositions for use in treating skin disorders
KR20250008740A (ko) * 2022-05-05 2025-01-15 카마리 파마 리미티드 피부 병태 및 이의 증상을 치료하는 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7818805B2 (en) 2004-09-09 2010-10-19 Avaya Inc. Methods and systems for network traffic security
US9617214B2 (en) * 2013-11-08 2017-04-11 The Translational Genomics Research Institute Compounds for cognitive enhancement and methods of use thereof
US20180194768A1 (en) * 2015-04-24 2018-07-12 President And Fellows Of Harvard College Substrate selective inhibitors of insulin degrading enzyme (ide) and uses thereof
US11078188B2 (en) 2017-03-08 2021-08-03 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Vogel's Encyclopedia of Practical Organic Chemistry", 1991, LONGMAN SCIENTIFIC AND TECHNICAL LTD., pages: 809 - 816
CATERINA ET AL., NATURE, vol. 389, 1997, pages 816 - 824
CLAPHAM ET AL., PHARMACOL REV, vol. 55, 2003, pages 591 - 596
DATABASE PUBCHEM SUBSTANCE 12 February 2015 (2015-02-12), "SUBSTANCE RECORD SCHEMBL4441225", XP055846303, Database accession no. SID 230369822 *
DATABASE PUBCHEM SUBSTANCE 29 March 2011 (2011-03-29), "SUBSTANCE RECORD SID 116084532", XP055846301, Database accession no. SID 116084532 *
DOTTO, CRIT REV ORAL BIOL MED, vol. 10, 1999, pages 442 - 457
HELLER, ACC. CHEM. RES., vol. 23, 1990, pages 128
HOENDERHOP ET AL., J PHYSIOLOGY, vol. 537, 2001, pages 747 - 761
LEBWOHLALI, J AM ACAD DERMATOL, vol. 45, 2001, pages 487 - 498
RUSH ET AL., J PHYSIOLOGY, vol. 564, 2005, pages 808 - 815
See also references of EP4096661A4
WEERAPURA ET AL., J PHYSIOLOGY, vol. 540, 2002, pages 15 - 27

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214375A1 (en) * 2022-05-05 2023-11-09 Kamari Pharma Ltd. Methods of treating dermatological conditions and symptoms thereof
CN117164527A (zh) * 2022-05-25 2023-12-05 大连理工大学 一种钒催化杂环芳香腈水解制备杂环芳香酰胺的方法
WO2024099404A1 (zh) 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种含氮螺环类化合物、药物组合物以及其用途
EP4617265A1 (en) 2022-11-10 2025-09-17 Prime Gene Therapeutics Co., Ltd. Nitrogen-containing spirocyclic compound, pharmaceutical composition and use thereof
EP4617267A4 (en) * 2022-11-10 2026-02-18 Prime Gene Therapeutics Co Ltd Thioether compound having mild medicinal properties and its use, pharmaceutical composition and associated uses

Also Published As

Publication number Publication date
IL295088B1 (en) 2025-12-01
AU2021212754A1 (en) 2022-08-04
EP4574822A2 (en) 2025-06-25
US20220332697A1 (en) 2022-10-20
US11807621B2 (en) 2023-11-07
EP4096661A1 (en) 2022-12-07
KR20220139299A (ko) 2022-10-14
CN115335050B (zh) 2024-05-17
JP2025175030A (ja) 2025-11-28
EP4574822A3 (en) 2025-08-27
PL4096661T3 (pl) 2025-09-01
ES3032872T3 (en) 2025-07-28
EP4096661A4 (en) 2024-03-06
BR112022014933A2 (pt) 2022-09-20
KR102735703B1 (ko) 2024-11-28
CN118702672A (zh) 2024-09-27
IL324069A (en) 2025-12-01
NZ790364A (en) 2025-12-19
IL295088B2 (en) 2026-04-01
EP4096661B1 (en) 2025-04-02
CA3168103A1 (en) 2021-08-05
US12435061B2 (en) 2025-10-07
CN115335050A (zh) 2022-11-11
US20240124413A1 (en) 2024-04-18
JP2023512664A (ja) 2023-03-28
EP4096661C0 (en) 2025-04-02
HUE071972T2 (hu) 2025-10-28
IL295088A (en) 2022-09-01
JP7785004B2 (ja) 2025-12-12

Similar Documents

Publication Publication Date Title
US12435061B2 (en) Compounds and compositions for use in treating skin disorders
CN110300589B (zh) 作为cftr增效剂的双环异杂芳基衍生物
CN105263326B (zh) 甲基/氟-吡啶基-甲氧基取代的吡啶酮-吡啶基化合物及氟-嘧啶基-甲氧基取代的吡啶酮-吡啶基化合物
TW201625599A (zh) 經取代之四氫哌喃及使用方法
TW200835481A (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
JP2020526543A (ja) ロイシンリッチリピートキナーゼ２の阻害剤
CA2841178A1 (en) Notch pathway signaling inhibitor compound
EP3596084A1 (en) 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
EP3573975A1 (en) Compounds
WO2019154252A1 (zh) 取代的烟酰胺类化合物及药物组合物及其用途
BR122024002638B1 (pt) Compostos e usos destes
BR122024002638A2 (pt) Compostos, composições compreendendo os mesmos, e usos destes
BR112022014933B1 (pt) Compostos ou sal farmaceuticamente aceitável dos mesmos e usos dos mesmos
HK40082455A (en) Compounds and compositions for use in treating skin disorders
HK40082455B (zh) 用於治疗皮肤病症的化合物和组合物
JP2020519694A (ja) オレキシン受容体アンタゴニス
CN117460718A (zh) 三嗪衍生物及其在癌症的治疗中的用途
CN109863147B (zh) 具有erk激酶抑制活性的化合物及其用途
CN117651698A (zh) 吡啶酮mk2抑制剂及其用途
CN117024441A (zh) 一种mat2a抑制剂
CN120530120A (zh) 可用作mk2激酶的降解剂的化合物和组合物
CN120817949A (zh) 作为wrn抑制剂的化合物及其应用
HK40055451A (en) Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21748179

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3168103

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022545405

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021212754

Country of ref document: AU

Date of ref document: 20210128

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022014933

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021748179

Country of ref document: EP

Effective date: 20220829

ENP Entry into the national phase

Ref document number: 112022014933

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220728

WWG Wipo information: grant in national office

Ref document number: 2021748179

Country of ref document: EP

WWD Wipo information: divisional of initial pct application

Ref document number: 324069

Country of ref document: IL

WWP Wipo information: published in national office

Ref document number: 324069

Country of ref document: IL

WWD Wipo information: divisional of initial pct application

Ref document number: 827808

Country of ref document: NZ

WWD Wipo information: divisional of initial pct application

Ref document number: 829424

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 790364

Country of ref document: NZ